AKBA vs TECH · rev $160.2M vs P/E 65, rev $1.22B
Akebia Ther (AKBA) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Akebia Ther (AKBA) is a drug manufacturers - specialty & generic company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported AKBA revenue for 2024-12-31 was $160.2M. Net income was -$69.4M. Revenue was down 17.7% from 2023-12-31 to 2024-12-31. AKBA currently screens at market cap $260.1M.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
AKBA currently screens at market cap $260.1M. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the AKBA and TECH stock pages for the full models.
Not investment advice.